Patents Examined by Howard E. Schain
  • Patent number: 5607920
    Abstract: The invention is directed to purified and isolated concanavalin A-binding proteins from chondrocytes that are not present in dedifferentiated cells from chondrocytes. The invention is also directed to a purified and isolated chondrocyte membrane protein, (CMP), which is a concanavalin A-binding protein, with a molecular weight of about 76 kD in SDS-PAGE. After treatment with endoglycosidase, CMP has an apparent molecular weight of about 67 kD. The N-terminal amino acid sequence and several internal amino acid sequences are given for CMP. These proteins can be used in assays, methods, or treatments involving differentiation of chondrocytes and the control of cartilaginous osteogenesis.
    Type: Grant
    Filed: July 21, 1994
    Date of Patent: March 4, 1997
    Assignee: Hoechst Japan Limited
    Inventors: Yukio Kato, Haiou Pan, Kazuyuki Doi
  • Patent number: 5605885
    Abstract: The present invention includes methods and compositions for affecting the immune system in animals and humans. The methods and compositions include the administration of prolactin agonists to an immunosuppressed animal or human thereby stimulating the immune system. In addition, the present invention includes a vaccine adjuvant comprising the administration of a prolactin agonist with the vaccine.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: February 25, 1997
    Assignee: EntreMed, Inc.
    Inventors: Edward W. Bernton, John W. Holaday, Henry U. Bryant
  • Patent number: 5605613
    Abstract: Coated capillary electrophoresis columns and methods for their use in electrophoretic separations are disclosed. The coated capillary columns include a length of tubing having an interior surface having an interconnected polymeric coating. The interconnected polymeric coating includes a hydrophobic hydrocarbon polymeric functionality covalently bound to the interior surface and polyvinylalcohol interconnected with the hydrophobic polymeric functionality. Exemplary columns are prepared by causing a Si-OH reactive compound, having a hydrophobic polymeric functionality, to react with Si-OH functionalities on the interior surface of capillary columns. Then causing vinyl acetate to polymerize in contact with the hydrophobic polymeric functionality and hydrolyzing the resulting polyvinylacetate forms a coating of interconnecting hydrophilic and hydrophobic polymers.
    Type: Grant
    Filed: January 27, 1995
    Date of Patent: February 25, 1997
    Assignee: Beckman Instruments, Inc.
    Inventor: Chia-Hui Shieh
  • Patent number: 5604202
    Abstract: This invention relates to the use of neuronotrophic factors, such as nerve growth factor (NGF), ciliary derived neuronotrophic factor (CNTF), brain derived neuronotrophic factor (BDNF), neuronotrophin-3 (NT-3), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor .varies. (TFG-.varies.), transforming growth factor .beta. (TGF-.beta.) and others to prevent drug-induced neuropathy.
    Type: Grant
    Filed: November 17, 1993
    Date of Patent: February 18, 1997
    Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
    Inventors: John A. Kessler, Stuart C. Apfel
  • Patent number: 5602229
    Abstract: Pentapeptide antibiotics of the formula ##STR1## wherein W, Z, X.sub.1, X.sub.2 and T represent the relative portions of an antibiotic of the dalbaheptide group (glycopeptide antibiotics), Y represents a carboxyacid group, a functional derivative of a carboxyacid group or a hydroxymethyl group. The invention includes the salts of the above represented pentapeptide antibiotics with acids or bases as well as their inner salts.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: February 11, 1997
    Assignee: Gruppo Lepetit S.p.A.
    Inventors: Adriano Malabarba, Romeo Ciabatti, J urgen K. Kettenring
  • Patent number: 5602231
    Abstract: A process for the solid phase synthesis of peptides containing a C-terminal aza-amino acid, for example the decapeptide goserelin, which comprises:(i) reacting an active ester or imidazolide of an N-protected aza-amino acid either with an appropriate reactive solid support in the case of the synthesis of a peptide containing a C-terminal aza-amino acid, or with a peptide which is attached to a solid support in the case of the synthesis of a peptide containing a non-C-terminal aza-amino acid;(ii) carrying out further conventional solid phase peptide synthesis steps to add sequentially further amino acids, to form a peptide with the required amino acid sequence bound to the solid support;(iii) cleaving the peptide from the solid support, and optionally(iv) reacting the product so formed with hydrazine to remove any acyl groups which have been formed on serine, arginine, tyrosine, threonine or hydroxyproline during the synthesis.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: February 11, 1997
    Assignee: Zeneca Limited
    Inventors: Ronald Cotton, Michael B. Giles
  • Patent number: 5602298
    Abstract: A method for processing waste material converts organic matter such as non-pretreated infectious hospital wastes, hazardous wastes, refinery wastes, paper wastes and other similar gaseous, liquid, or solid organic wastes, into hydrogen and carbon by photodecomposition. The waste material is converted by exposing the organic waste materials to a sufficiently intense field of radiation which causes the decomposition, or breakdown, of the organic materials into their component elements. Because the environment within the reaction chamber is controlled to minimize the presence of oxidizing agents, the decomposition products, primarily carbon and hydrogen, can be withdrawn and collected for subsequent use.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: February 11, 1997
    Assignee: Advanced Waste Treatment Technology, Inc.
    Inventor: George B. Levin
  • Patent number: 5599433
    Abstract: A buffer and method useful for the analysis of glycoproteins by capillary zone electrophoresis. The buffer comprises water, a sugar complexing compound, a base compound for adjusting the pH, and a zwitterionic compound. An embodiment of the buffer comprises sodium borate as the complexing compound, sodium hydroxide as the base, and 3-cyclohexylamino-1-propanesulfonic acid as the zwitterionic compound. In the method, a selected glycoprotein is subjected to capillary zone electrophoresis. The proportion or the amount of the glycoprotein is determined by quantitative analysis of the resulting electropherogram.
    Type: Grant
    Filed: January 17, 1995
    Date of Patent: February 4, 1997
    Assignee: Beckman Instruments, Inc.
    Inventors: Nida Keo, Zara Safarian, Cheng-Ming Liu, Hann-Ping Wang
  • Patent number: 5597802
    Abstract: A formulation for IGF-I is disclosed that is useful in treating hyperglycemic disorders and, in combination with growth hormone, in enhancing growth of a mammal. Also disclosed is a process for preparing a formulation of growth hormone and IGF-I from the IGF-I formulation. The IGF-I formulation comprises about 2-20 mg/ml of IGF-I, about 2-50 mg/ml of an osmolyte, about 1-15 mg/ml of a stabilizer, and a buffered solution at about pH 5-5.5, optionally with a surfactant.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 28, 1997
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Douglas A. Yeung, James Q. Oeswein
  • Patent number: 5597702
    Abstract: Detection of lead present in a sample, comprising the steps of: (a) adding a lead recovery agent to an assay solution containing lead from the sample; (b) adding to the assay solution a disulfide enzyme which is inhibited in the presence of lead; and (c) correlating the activity of the disulfide enzyme to the amount of lead in the sample. The lead recovery agent enhances the sensitivity and accuracy of the assay such that the assay can be readily automated for detection of lead in whole blood using commercially available automation systems.
    Type: Grant
    Filed: December 9, 1994
    Date of Patent: January 28, 1997
    Assignee: Abbott Laboratories
    Inventors: Martin Wong, David M. Finley, John M. Ramp, Gary L. Boltinghouse, Jr., Mark R. Shaffar, Stephen D. Stroupe, John M. Brackett
  • Patent number: 5597797
    Abstract: A method is disclosed for treating obese mammals or preventing obesity from occurring in mammals. This method involves administering to the mammal an effective amount of growth hormone in combination with an effective amount of IGF-I. Preferably, the growth hormone is given so as to have a maintained, continual therapeutically effective presence in the blood, such as by continuous infusion or frequent injections, or by use of a long-acting formulation.
    Type: Grant
    Filed: November 19, 1993
    Date of Patent: January 28, 1997
    Assignee: Genentech, Inc.
    Inventor: Ross G. Clark
  • Patent number: 5594102
    Abstract: The present invention is directed to a chemical process for preparing antibiotic L 17392 (deglucoteicoplanin) and its salts with bases and acids by submitting a teicoplanin compound or a teicoplanin-like compound to controlled strong acid hydrolysis in the presence of an organic aprotic solvent, and a purification thereof.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: January 14, 1997
    Assignee: Gruppo Lepetit S.p.A
    Inventors: Giambattista Panzone, Anacleto Gianantonio
  • Patent number: 5591711
    Abstract: L-lysyl-glycyl-histidine and metal complexes thereof, for example, L-lysyl-glycyl-L-histidine: copper (II).The L-lysyl-glycyl-L-histidine and salt thereof have a fibroblast proliferation promoting activity and then it is useful as a wound healing agent.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: January 7, 1997
    Assignee: Hoechst Japan Limited
    Inventors: Masayoshi Koyama, Mikiko Takahashi, Masayoshi Yanagawa
  • Patent number: 5589461
    Abstract: A method of inhibiting the proliferation rate of hepatocytes in a subject by administering to the subject the free tripeptide of the composition SDK (serine-aspartic acid-lysine) or the salt thereof.
    Type: Grant
    Filed: May 17, 1994
    Date of Patent: December 31, 1996
    Inventor: G. Ruhenstroth-Bauer
  • Patent number: 5585348
    Abstract: This invention relates to a method of preventing hyperalgesia and other undesirable side-effects associated with the administration of growth factor, including nerve growth factor, utilizing an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway. In addition, this invention relates to a composition comprising a growth factor and an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway.
    Type: Grant
    Filed: August 13, 1993
    Date of Patent: December 17, 1996
    Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
    Inventors: Stanley M. Crain, Ke-fei Shen, John A. Kessler, Stuart C. Apfel
  • Patent number: 5585099
    Abstract: The present invention relates to a composition for enhancing the immune response of an animal to an infectious disease vaccine wherein the composition comprises prolactin. Preferably, the composition is human prolactin and the animal to be vaccinated is, as well, human.The present invention further relates to a composition for enhancing the immune response of an animal to an infectious disease vaccine wherein the composition comprises prolactin cDNA. Human prolactin cDNA is preferred.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: December 17, 1996
    Assignee: Genzyme Corporation
    Inventors: Susan Richards, Johanne Kaplan, Richard Moscicki
  • Patent number: 5578575
    Abstract: A method for treating septic shock by administering a retroinverted tetrapeptides of formula I ##STR1## wherein R is a hydrogen atom or the side-chain of threonine; R.sub.1 is the side-chain of arginine, leucine or glutamine; and R.sub.2 is a hydrogen atom or a metabolically perishable acyl group; with the proviso that when R.sub.1 is the side-chain of arginine, R cannot be the side-chain of threonine; diastereo-isomeric forms and pharmacologically acceptable salts, esters and amides thereof.
    Type: Grant
    Filed: February 28, 1996
    Date of Patent: November 26, 1996
    Assignee: Italfarmaco S.P.A.
    Inventors: Antonio S. Verdini, Massimo Pinori, Silvana Cappelletti, Laura Gazerro, Flavio Leoni
  • Patent number: 5576295
    Abstract: Agents for suppressing the motor activity of gastrointestinal tracts, which comprise glicentin as an active ingredient. They can be used as an adjunct for use in examination of gastrointestinal tracts by radiography or endoscopy.
    Type: Grant
    Filed: October 18, 1994
    Date of Patent: November 19, 1996
    Assignee: Nisshin Flour Milling Co., Ltd.
    Inventors: Seiki Matsuno, Iwao Sasaki, Akira Ohneda, Kazuyuki Sasaki
  • Patent number: 5574017
    Abstract: The present invention provides methods and pharmaceutical preparations for inhibiting the growth of bacterial microorganisms.
    Type: Grant
    Filed: July 5, 1994
    Date of Patent: November 12, 1996
    Inventor: William G. Gutheil
  • Patent number: 5571789
    Abstract: The present invention relates to the use of a pharmaceutic composition containing urodilatin as an active substance and optionally pharmaceutically usual diluents, excipients, fillers or adjuvants for treating pulmonary and/or bronchial diseases.
    Type: Grant
    Filed: November 15, 1994
    Date of Patent: November 5, 1996
    Assignee: Haemopep Pharma GmbH
    Inventors: Thomas Fl uge, Wolf-Georg Forssmann